Movement Alert｜PHARMARON Falls 3.38% in Regular Trading, Convertible Bond Dilution Concerns Persist Amid CXO Sector Weakness

Market Focus

Aug 28

On August 28, PHARMARON fell 3.38% in regular trading, trading at HK$29.18/share, with turnover of HK$57.24 million.

The decline is driven by continued market concerns over potential share dilution following the company's announcement to issue RMB 2.18 billion zero-coupon USD-settled convertible bonds due August 2027. The board formally approved the proposal on August 27. The initial conversion price is set at HK$36.08 per H share, representing a 16.76% premium to the August 26 closing price. If fully converted, approximately 70.48 million new H shares would be issued, accounting for 3.70% of the enlarged total share capital. The bonds were subscribed by no fewer than six independent investors, with settlement tentatively scheduled for September 2.

Additionally, the broader CXO sector continued to trade under pressure, with GENSCRIPT BIO down 4.34% and WUXI XDC down 3.77%, amplifying the downward momentum through sector-wide selling.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1105340122"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105340122\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105340122?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105340122","market":"us","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Falls 3.38% in Regular Trading, Convertible Bond Dilution Concerns Persist Amid CXO Sector Weakness","media":"Market Focus","content":"<p><p>On August 28, PHARMARON fell 3.38% in regular trading, trading at HK$29.18/share, with turnover of HK$57.24 million.</p><p>The decline is driven by continued market concerns over potential share dilution following the company's announcement to issue RMB 2.18 billion zero-coupon USD-settled convertible bonds due August 2027. The board formally approved the proposal on August 27. The initial conversion price is set at HK$36.08 per H share, representing a 16.76% premium to the August 26 closing price. If fully converted, approximately 70.48 million new H shares would be issued, accounting for 3.70% of the enlarged total share capital. The bonds were subscribed by no fewer than six independent investors, with settlement tentatively scheduled for September 2.</p><p>Additionally, the broader CXO sector continued to trade under pressure, with GENSCRIPT BIO down 4.34% and WUXI XDC down 3.77%, amplifying the downward momentum through sector-wide selling.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Falls 3.38% in Regular Trading, Convertible Bond Dilution Concerns Persist Amid CXO Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Falls 3.38% in Regular Trading, Convertible Bond Dilution Concerns Persist Amid CXO Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-28 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 28, PHARMARON fell 3.38% in regular trading, trading at HK$29.18/share, with turnover of HK$57.24 million.</p><p>The decline is driven by continued market concerns over potential share dilution following the company's announcement to issue RMB 2.18 billion zero-coupon USD-settled convertible bonds due August 2027. The board formally approved the proposal on August 27. The initial conversion price is set at HK$36.08 per H share, representing a 16.76% premium to the August 26 closing price. If fully converted, approximately 70.48 million new H shares would be issued, accounting for 3.70% of the enlarged total share capital. The bonds were subscribed by no fewer than six independent investors, with settlement tentatively scheduled for September 2.</p><p>Additionally, the broader CXO sector continued to trade under pressure, with GENSCRIPT BIO down 4.34% and WUXI XDC down 3.77%, amplifying the downward momentum through sector-wide selling.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1105340122","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105340122","pubTimestamp":1787884552,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 28, PHARMARON fell 3.38% in regular trading, trading at HK$29.18/share, with turnover of HK$57.24 million.The decline is driven by continued market concerns over potential share dilution...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势警报|康龙化成常规交易下跌3.38%，CXO板块疲软中可转债稀释担忧持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 28, PHARMARON fell 3.38% in regular trading, trading at HK$29.18/share, with turnover of HK$57.24 million.The decline is driven by continued market concerns over potential share dilution following the company's announcement to issue RMB 2.18 billion zero-coupon USD-settled convertible bonds due August 2027. The board formally approved the proposal on August 27. The initial conversion price is set at HK$36.08 per H share, representing a 16.76% premium to the August 26 closing price. If fully converted, approximately 70.48 million new H shares would be issued, accounting for 3.70% of the enlarged total share capital. The bonds were subscribed by no fewer than six independent investors, with settlement tentatively scheduled for September 2.Additionally, the broader CXO sector continued to trade under pressure, with GENSCRIPT BIO down 4.34% and WUXI XDC down 3.77%, amplifying the downward momentum through sector-wide selling.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}